CN103108876A - 用于抗病毒治疗的2’-氟取代的carba-核苷类似物 - Google Patents
用于抗病毒治疗的2’-氟取代的carba-核苷类似物 Download PDFInfo
- Publication number
- CN103108876A CN103108876A CN2011800449231A CN201180044923A CN103108876A CN 103108876 A CN103108876 A CN 103108876A CN 2011800449231 A CN2011800449231 A CN 2011800449231A CN 201180044923 A CN201180044923 A CN 201180044923A CN 103108876 A CN103108876 A CN 103108876A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- independently
- another aspect
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCNP(C)(C)=* Chemical compound CCNP(C)(C)=* 0.000 description 7
- AENSHNRNBKEIJK-KQKLOKAKSA-N CC(C)OC([C@H](C)NP(OC[C@H]1O[C@]2(c3ccc4[n]3ncnc4N)C#N)(O[C@H]1[C@@]2(C)F)=O)=O Chemical compound CC(C)OC([C@H](C)NP(OC[C@H]1O[C@]2(c3ccc4[n]3ncnc4N)C#N)(O[C@H]1[C@@]2(C)F)=O)=O AENSHNRNBKEIJK-KQKLOKAKSA-N 0.000 description 1
- NYJKISSOEZMRHH-POXGOYDTSA-N CC(C)OC([C@H](C)N[P@](Oc1ccccc1)(Oc(cc1)ccc1[N+]([O-])=O)=O)=O Chemical compound CC(C)OC([C@H](C)N[P@](Oc1ccccc1)(Oc(cc1)ccc1[N+]([O-])=O)=O)=O NYJKISSOEZMRHH-POXGOYDTSA-N 0.000 description 1
- WGEGHZSJVGUASV-UHFFFAOYSA-N CC12C=CC(OCCNC(N)=O)=CC1C2 Chemical compound CC12C=CC(OCCNC(N)=O)=CC1C2 WGEGHZSJVGUASV-UHFFFAOYSA-N 0.000 description 1
- IVRSKCADIUFFTB-PWGGDVMCSA-N CCC(C([C@H]1O)=[O]C(CC/N=C(/C(N)=C)\N(C)N)[C@]1(C)F)O Chemical compound CCC(C([C@H]1O)=[O]C(CC/N=C(/C(N)=C)\N(C)N)[C@]1(C)F)O IVRSKCADIUFFTB-PWGGDVMCSA-N 0.000 description 1
- HBBQNAOQGVDSCS-XPYFYPHYSA-N CCC(CC)COC(C(C)(C)NP(OC[C@H]([C@H]([C@@]1(C)F)O)O[C@]1(c1ccc2[n]1ncnc2N)C#N)(Oc1ccccc1)=O)=O Chemical compound CCC(CC)COC(C(C)(C)NP(OC[C@H]([C@H]([C@@]1(C)F)O)O[C@]1(c1ccc2[n]1ncnc2N)C#N)(Oc1ccccc1)=O)=O HBBQNAOQGVDSCS-XPYFYPHYSA-N 0.000 description 1
- DXDRDUVUCWFQBY-VIFPVBQESA-N CCCCCCCOC([C@H](C)N)=O Chemical compound CCCCCCCOC([C@H](C)N)=O DXDRDUVUCWFQBY-VIFPVBQESA-N 0.000 description 1
- UXKVNYDSSLCGRM-VIFPVBQESA-N CCCCCCCOC([C@H](C)NCl)=O Chemical compound CCCCCCCOC([C@H](C)NCl)=O UXKVNYDSSLCGRM-VIFPVBQESA-N 0.000 description 1
- NLOWIPAVMGINSO-NGXIVSIZSA-N CCOC([C@H](C)NP(Oc1ccccc1)(Oc(cc1)ccc1[N+]([O-])=O)=O)=O Chemical compound CCOC([C@H](C)NP(Oc1ccccc1)(Oc(cc1)ccc1[N+]([O-])=O)=O)=O NLOWIPAVMGINSO-NGXIVSIZSA-N 0.000 description 1
- WSAKVRUWUHFQHB-SOWFJZOFSA-N CCOC([C@H](CCS(C)(=O)=O)NP(OCC(C(C)[C@@](c1ccc2[n]1ncnc2N)(C#N)OC)O)(Oc1ccccc1)=O)=O Chemical compound CCOC([C@H](CCS(C)(=O)=O)NP(OCC(C(C)[C@@](c1ccc2[n]1ncnc2N)(C#N)OC)O)(Oc1ccccc1)=O)=O WSAKVRUWUHFQHB-SOWFJZOFSA-N 0.000 description 1
- LAIJPMAFUSSHLO-STFFIMJZSA-N CCOC([C@H](CCSC)NP(Oc(cc1)ccc1[N+]([O-])=O)(OC1=CCCC=C1)=O)=O Chemical compound CCOC([C@H](CCSC)NP(Oc(cc1)ccc1[N+]([O-])=O)(OC1=CCCC=C1)=O)=O LAIJPMAFUSSHLO-STFFIMJZSA-N 0.000 description 1
- COYPZADTXISTSJ-UHFFFAOYSA-N CN(CCCN1)C1=O Chemical compound CN(CCCN1)C1=O COYPZADTXISTSJ-UHFFFAOYSA-N 0.000 description 1
- BILRZDHBILTSKU-FZZIBODNSA-N C[C@@]1([C@@](c2ccc3[n]2ncnc3N)(C#N)O[C@H](COP(O)([O]=C)=O)C1)F Chemical compound C[C@@]1([C@@](c2ccc3[n]2ncnc3N)(C#N)O[C@H](COP(O)([O]=C)=O)C1)F BILRZDHBILTSKU-FZZIBODNSA-N 0.000 description 1
- BNWKIMUJGYHAIU-UHFFFAOYSA-N Cc(cc1)ccc1NCC(N(C)C)=O Chemical compound Cc(cc1)ccc1NCC(N(C)C)=O BNWKIMUJGYHAIU-UHFFFAOYSA-N 0.000 description 1
- JIPPLQKITODFEO-UHFFFAOYSA-N Cc(cc1)ccc1NCC(N)=O Chemical compound Cc(cc1)ccc1NCC(N)=O JIPPLQKITODFEO-UHFFFAOYSA-N 0.000 description 1
- ZUSCIMZVMLVQAT-UHFFFAOYSA-N Cc(cc1)ccc1OCCC(N)=O Chemical compound Cc(cc1)ccc1OCCC(N)=O ZUSCIMZVMLVQAT-UHFFFAOYSA-N 0.000 description 1
- WWGKAIVKCGQLSR-UHFFFAOYSA-N Cc(cc1)ccc1OCCOC(N)=O Chemical compound Cc(cc1)ccc1OCCOC(N)=O WWGKAIVKCGQLSR-UHFFFAOYSA-N 0.000 description 1
- TXFOLHZMICYNRM-UHFFFAOYSA-N O=P(Oc1ccccc1)(Cl)Cl Chemical compound O=P(Oc1ccccc1)(Cl)Cl TXFOLHZMICYNRM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/885,917 US7973013B2 (en) | 2009-09-21 | 2010-09-20 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US12/885,917 | 2010-09-20 | ||
| US13/050,820 US8455451B2 (en) | 2009-09-21 | 2011-03-17 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US13/050,820 | 2011-03-17 | ||
| PCT/US2011/029441 WO2012039791A1 (en) | 2010-09-20 | 2011-03-22 | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103108876A true CN103108876A (zh) | 2013-05-15 |
Family
ID=47748238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800449231A Pending CN103108876A (zh) | 2010-09-20 | 2011-03-22 | 用于抗病毒治疗的2’-氟取代的carba-核苷类似物 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2619206A1 (enExample) |
| JP (4) | JP2013538230A (enExample) |
| KR (1) | KR101879887B1 (enExample) |
| CN (1) | CN103108876A (enExample) |
| AP (1) | AP3699A (enExample) |
| AU (1) | AU2011306066B2 (enExample) |
| BR (1) | BR112013008017A2 (enExample) |
| CA (1) | CA2807496C (enExample) |
| CL (1) | CL2013000727A1 (enExample) |
| CO (1) | CO6680669A2 (enExample) |
| CR (1) | CR20130172A (enExample) |
| EA (1) | EA026523B1 (enExample) |
| EC (1) | ECSP13012560A (enExample) |
| IL (1) | IL225221A0 (enExample) |
| MA (1) | MA34593B1 (enExample) |
| MX (1) | MX2013003179A (enExample) |
| NZ (1) | NZ608070A (enExample) |
| PE (3) | PE20171624A1 (enExample) |
| PH (1) | PH12013500311B1 (enExample) |
| SG (1) | SG188223A1 (enExample) |
| WO (1) | WO2012039791A1 (enExample) |
| ZA (1) | ZA201301042B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104230985A (zh) * | 2014-09-01 | 2014-12-24 | 北京天弘天达医药科技有限公司 | (s)-2-[(s)-(4-硝基-苯氧基)-苯氧基-磷酰基氨基]丙酸异丙酯的制备方法 |
| CN110003215A (zh) * | 2013-11-11 | 2019-07-12 | 吉利德科学公司 | 可用于治疗呼吸道合胞病毒感染的吡咯并[1,2-f][1,2,4]三嗪 |
| WO2023207942A1 (zh) * | 2022-04-25 | 2023-11-02 | 北京沐华生物科技有限责任公司 | 用于治疗或预防冠状病毒感染的核苷类药物及其用途 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038946T2 (hu) | 2008-04-23 | 2018-12-28 | Gilead Sciences Inc | 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre |
| JP5767643B2 (ja) | 2009-09-21 | 2015-08-19 | ギリード・サイエンシズ・インコーポレーテッド | １’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体 |
| KR101995598B1 (ko) | 2010-07-19 | 2019-07-02 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
| PE20130400A1 (es) | 2010-07-22 | 2013-04-10 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae |
| TW201701876A (zh) | 2010-12-20 | 2017-01-16 | 吉李德科學股份有限公司 | 治療ｃ型肝炎病毒（ｈｃｖ）之方法 |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| PL2950786T3 (pl) | 2013-01-31 | 2020-05-18 | Gilead Pharmasset Llc | Formulacja skojarzona dwóch związków przeciwwirusowych |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| PT3349758T (pt) | 2015-09-16 | 2022-07-13 | Gilead Sciences Inc | Métodos para o tratamento de infeções pelo vírus arenaviridae |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
| US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
| JP7482250B2 (ja) | 2020-04-06 | 2024-05-13 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノ置換カルバヌクレオシド類似体の吸入製剤 |
| PL4157272T3 (pl) | 2020-05-29 | 2025-10-20 | Gilead Sciences, Inc. | Remdesiwir do leczenia zakażeń wirusowych |
| JP2023531524A (ja) | 2020-06-24 | 2023-07-24 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシド類似体及びその使用 |
| LT4204421T (lt) * | 2020-08-27 | 2024-06-25 | Gilead Sciences, Inc. | Virusinių infekcijų gydymui skirti junginiai ir būdai |
| US20230295172A1 (en) | 2022-03-02 | 2023-09-21 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1498221A (zh) * | 2001-01-22 | 2004-05-19 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 | |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| WO2009132123A1 (en) * | 2008-04-23 | 2009-10-29 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| WO2010002877A2 (en) * | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| CN102596958A (zh) * | 2009-09-21 | 2012-07-18 | 吉里德科学公司 | 用于抗病毒治疗的2’-氟代carba-核苷类似物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| WO1991019721A1 (en) | 1990-06-13 | 1991-12-26 | Arnold Glazier | Phosphorous produgs |
| ES2118069T3 (es) | 1990-09-14 | 1998-09-16 | Acad Of Science Czech Republic | Profarmacos de fosfonatos. |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| SK11922002A3 (sk) | 2000-02-18 | 2003-06-03 | Shire Biochem Inc. | Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| DK2251015T3 (da) | 2000-10-18 | 2013-05-13 | Gilead Pharmasset Llc | Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation |
| US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| WO2004046331A2 (en) | 2002-11-15 | 2004-06-03 | Idenix (Cayman) Limited | 2’-branched nucleosides and flaviviridae mutation |
| EP2345659A1 (en) * | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| ES2769377T3 (es) | 2004-09-14 | 2020-06-25 | Gilead Pharmasset Llc | Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo |
| US20080280842A1 (en) * | 2004-10-21 | 2008-11-13 | Merck & Co., Inc. | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| JP2010515680A (ja) | 2007-01-05 | 2010-05-13 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート |
| NZ578556A (en) | 2007-01-12 | 2012-04-27 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| JP2010522241A (ja) | 2007-03-21 | 2010-07-01 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物 |
| US8242085B2 (en) | 2007-05-10 | 2012-08-14 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer |
| WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| KR101834707B1 (ko) * | 2009-02-10 | 2018-03-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 |
-
2011
- 2011-03-22 SG SG2013011325A patent/SG188223A1/en unknown
- 2011-03-22 CA CA2807496A patent/CA2807496C/en active Active
- 2011-03-22 AU AU2011306066A patent/AU2011306066B2/en active Active
- 2011-03-22 NZ NZ608070A patent/NZ608070A/en unknown
- 2011-03-22 EA EA201390141A patent/EA026523B1/ru unknown
- 2011-03-22 PH PH1/2013/500311A patent/PH12013500311B1/en unknown
- 2011-03-22 WO PCT/US2011/029441 patent/WO2012039791A1/en not_active Ceased
- 2011-03-22 KR KR1020137010012A patent/KR101879887B1/ko active Active
- 2011-03-22 MX MX2013003179A patent/MX2013003179A/es not_active Application Discontinuation
- 2011-03-22 PE PE2017001530A patent/PE20171624A1/es unknown
- 2011-03-22 EP EP11715792.5A patent/EP2619206A1/en not_active Withdrawn
- 2011-03-22 PE PE2022003082A patent/PE20230684A1/es unknown
- 2011-03-22 JP JP2013529139A patent/JP2013538230A/ja not_active Withdrawn
- 2011-03-22 CN CN2011800449231A patent/CN103108876A/zh active Pending
- 2011-03-22 PE PE2013000530A patent/PE20131165A1/es active IP Right Grant
- 2011-03-22 BR BR112013008017A patent/BR112013008017A2/pt not_active Application Discontinuation
- 2011-03-22 AP AP2013006767A patent/AP3699A/en active
-
2013
- 2013-02-07 ZA ZA2013/01042A patent/ZA201301042B/en unknown
- 2013-02-26 CO CO13038918A patent/CO6680669A2/es not_active Application Discontinuation
- 2013-03-14 IL IL225221A patent/IL225221A0/en unknown
- 2013-03-18 CL CL2013000727A patent/CL2013000727A1/es unknown
- 2013-04-04 MA MA35795A patent/MA34593B1/fr unknown
- 2013-04-17 CR CR20130172A patent/CR20130172A/es unknown
- 2013-04-18 EC ECSP13012560 patent/ECSP13012560A/es unknown
-
2016
- 2016-01-18 JP JP2016006833A patent/JP2016074732A/ja not_active Withdrawn
-
2017
- 2017-04-10 JP JP2017077366A patent/JP6475280B2/ja active Active
-
2018
- 2018-09-18 JP JP2018173758A patent/JP2019014726A/ja not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1498221A (zh) * | 2001-01-22 | 2004-05-19 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 | |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| WO2009132123A1 (en) * | 2008-04-23 | 2009-10-29 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| WO2010002877A2 (en) * | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| CN102596958A (zh) * | 2009-09-21 | 2012-07-18 | 吉里德科学公司 | 用于抗病毒治疗的2’-氟代carba-核苷类似物 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110003215A (zh) * | 2013-11-11 | 2019-07-12 | 吉利德科学公司 | 可用于治疗呼吸道合胞病毒感染的吡咯并[1,2-f][1,2,4]三嗪 |
| CN114085243A (zh) * | 2013-11-11 | 2022-02-25 | 吉利德科学公司 | 可用于治疗呼吸道合胞病毒感染的吡咯并[1,2-f][1,2,4]三嗪 |
| CN114085243B (zh) * | 2013-11-11 | 2024-04-26 | 吉利德科学公司 | 可用于治疗呼吸道合胞病毒感染的吡咯并[1,2-f][1,2,4]三嗪 |
| CN104230985A (zh) * | 2014-09-01 | 2014-12-24 | 北京天弘天达医药科技有限公司 | (s)-2-[(s)-(4-硝基-苯氧基)-苯氧基-磷酰基氨基]丙酸异丙酯的制备方法 |
| WO2023207942A1 (zh) * | 2022-04-25 | 2023-11-02 | 北京沐华生物科技有限责任公司 | 用于治疗或预防冠状病毒感染的核苷类药物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011306066B2 (en) | 2015-01-29 |
| SG188223A1 (en) | 2013-04-30 |
| IL225221A0 (en) | 2013-06-27 |
| KR101879887B1 (ko) | 2018-07-18 |
| CA2807496A1 (en) | 2012-03-29 |
| NZ608070A (en) | 2015-11-27 |
| ECSP13012560A (es) | 2013-06-28 |
| CO6680669A2 (es) | 2013-05-31 |
| PE20230684A1 (es) | 2023-04-21 |
| JP2016074732A (ja) | 2016-05-12 |
| JP2013538230A (ja) | 2013-10-10 |
| MA34593B1 (fr) | 2013-10-02 |
| AP3699A (en) | 2016-05-31 |
| PH12013500311A1 (en) | 2013-04-22 |
| ZA201301042B (en) | 2014-07-30 |
| CR20130172A (es) | 2013-05-29 |
| JP2019014726A (ja) | 2019-01-31 |
| WO2012039791A1 (en) | 2012-03-29 |
| PE20171624A1 (es) | 2017-11-02 |
| PE20131165A1 (es) | 2013-10-14 |
| JP6475280B2 (ja) | 2019-02-27 |
| EA201390141A1 (ru) | 2013-09-30 |
| AU2011306066A1 (en) | 2013-02-28 |
| MX2013003179A (es) | 2013-04-24 |
| CA2807496C (en) | 2019-01-22 |
| KR20130110168A (ko) | 2013-10-08 |
| CL2013000727A1 (es) | 2013-08-23 |
| JP2017119726A (ja) | 2017-07-06 |
| EA026523B1 (ru) | 2017-04-28 |
| BR112013008017A2 (pt) | 2016-06-14 |
| AP2013006767A0 (en) | 2013-03-31 |
| EP2619206A1 (en) | 2013-07-31 |
| PH12013500311B1 (en) | 2017-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018204449B2 (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| US8455451B2 (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| US7973013B2 (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| AU2011306066B2 (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| HK1236200B (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| HK1236200A1 (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| HK1173446B (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| HK1173446A (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| EA046452B1 (ru) | 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения | |
| OA16370A (en) | Mass transfert column. | |
| OA16347A (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment. | |
| OA16229A (en) | 2'-Fluoro substituted carba-nucleoside analogs for antiviral treatment. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130515 |